Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 4
2012 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Cell therapy and satellite centers: the Cardiovascular Cell Therapy Research Network experience.
Moyé LA, Henry TD, Baran KW, Bettencourt J, Bruhn-Ding B, Caldwell E, Chambers J, Flood K, Francescon J, Bowman S, Kappenman C, Kar B, Lambert C, LaRock J, Lerman A, Mazzurco S, Prashad R, Raveendran G, Simon D, Westbrook L, Simari RD. Moyé LA, et al. Contemp Clin Trials. 2011 Nov;32(6):841-7. doi: 10.1016/j.cct.2011.07.001. Epub 2011 Jul 8. Contemp Clin Trials. 2011. PMID: 21767663 Free PMC article. Review.
Quantification of myocardial segmental function in acute and chronic ischemic heart disease and implications for cardiovascular cell therapy trials: a review from the NHLBI-Cardiovascular Cell Therapy Research Network.
Petersen JW, Forder JR, Thomas JD, Moyé LA, Lawson M, Loghin C, Traverse JH, Baraniuk S, Silva G, Pepine CJ; CCTRN (Cardiovascular Cell Therapy Research Network). Petersen JW, et al. JACC Cardiovasc Imaging. 2011 Jun;4(6):671-9. doi: 10.1016/j.jcmg.2011.02.015. JACC Cardiovasc Imaging. 2011. PMID: 21679903 Free PMC article. Review.
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network. Traverse JH, et al. Tex Heart Inst J. 2010;37(4):412-20. Tex Heart Inst J. 2010. PMID: 20844613 Free PMC article. Clinical Trial.
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.
Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Willerson JT, et al. Am Heart J. 2010 Aug;160(2):215-23. doi: 10.1016/j.ahj.2010.03.029. Am Heart J. 2010. PMID: 20691824 Free PMC article. Clinical Trial.
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Traverse JH, et al. Am Heart J. 2009 Sep;158(3):356-63. doi: 10.1016/j.ahj.2009.06.009. Epub 2009 Jul 23. Am Heart J. 2009. PMID: 19699857 Free PMC article. Clinical Trial.
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.
Richman S, Gee AP, McKenna DH, Traverse JH, Henry TD, Fisk D, Pepine CJ, Bloom J, Willerson JT, Prater K, Zhao D, Koç JR, Anwaruddin S, Taylor DA, Cogle CR, Moyé LA, Simari RD, Skarlatos SI. Richman S, et al. Transfusion. 2012 Oct;52(10):2225-33. doi: 10.1111/j.1537-2995.2011.03543.x. Epub 2012 Feb 10. Transfusion. 2012. PMID: 22320233 Free PMC article.